INSPIRED MEDICINE!
Jan 14, 2019 5:16:11 GMT -5
sportsrancho, itellthefuture777, and 7 more like this
Post by tw12 on Jan 14, 2019 5:16:11 GMT -5
Dear Fellow Long-suffering MannKind Investors,
Good morning.
Here -- for us (anything but!) fools -- is a friendly reminder of a few facts in our financial favor:
* Our product, Technosphere, is inspired and disruptive technology. It’s astonishingly effective, proprietary for another ten years, and, in any case, extraordinarily difficult to reproduce.
* It has dozens of major marketplace applications.
* The initial market (diabtetics) is huge, worldwide, and growing rapidly.
* The duration of patient use is a lifetime.
* Substantial marketplace acceptance seems inevitable. Afrezza is gaining real traction; the second drug, Treprostinal, has a superb partner (United Therapeutics); and the rest of the line-up resonates with sophisticated and deep potential.
* Management is well experienced, hard working and, not least, dedicated to the extraordinary vision of Al Mann. In addition, it’s essentially a new team working for a new company; this helps to enhance focus and productivity.
* Promotion, while deficient these past few years, is easily fixed. In fact, Mike and his team are working hard to focus messaging much more effectively, beginning today.
* Even though efforts to disrupt the potential of the company have been incessant and pervasive -- both on the part of stock manipulators and of competitive businesses -- their influence will diminish against the overwhelming power of marketplace acceptance.
* And there is a world-class manufacturing facility in place in Danbury, ready and able to handle rapid growth.
So...MNKD seems indeed a wise investment, one that will offer not only inspired returns but also, most importantly, will enhance the lives of millions across the planet.
Now that's inspired medicine!
Good morning.
Here -- for us (anything but!) fools -- is a friendly reminder of a few facts in our financial favor:
* Our product, Technosphere, is inspired and disruptive technology. It’s astonishingly effective, proprietary for another ten years, and, in any case, extraordinarily difficult to reproduce.
* It has dozens of major marketplace applications.
* The initial market (diabtetics) is huge, worldwide, and growing rapidly.
* The duration of patient use is a lifetime.
* Substantial marketplace acceptance seems inevitable. Afrezza is gaining real traction; the second drug, Treprostinal, has a superb partner (United Therapeutics); and the rest of the line-up resonates with sophisticated and deep potential.
* Management is well experienced, hard working and, not least, dedicated to the extraordinary vision of Al Mann. In addition, it’s essentially a new team working for a new company; this helps to enhance focus and productivity.
* Promotion, while deficient these past few years, is easily fixed. In fact, Mike and his team are working hard to focus messaging much more effectively, beginning today.
* Even though efforts to disrupt the potential of the company have been incessant and pervasive -- both on the part of stock manipulators and of competitive businesses -- their influence will diminish against the overwhelming power of marketplace acceptance.
* And there is a world-class manufacturing facility in place in Danbury, ready and able to handle rapid growth.
So...MNKD seems indeed a wise investment, one that will offer not only inspired returns but also, most importantly, will enhance the lives of millions across the planet.
Now that's inspired medicine!
